Stifel Nicolaus Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)

Tip Ranks
2025.11.17 12:18
portai
I'm PortAI, I can summarize articles.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on VistaGen Therapeutics with a price target of $12.00. Matteis has an average return of 13.4% and a 49.15% success rate on recommended stocks. Maxim Group also issued a Buy rating, while TR reiterated a Hold rating on VistaGen Therapeutics.

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on VistaGen Therapeutics today and set a price target of $12.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Matteis covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and Xenon. According to TipRanks, Matteis has an average return of 13.4% and a 49.15% success rate on recommended stocks.

In addition to Stifel Nicolaus, VistaGen Therapeutics also received a Buy from Maxim Group’s Jason McCarthy in a report issued on November 14. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on VistaGen Therapeutics (NASDAQ: VTGN).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer